Managing symptoms improves quality of life.
Sleep disturbance, pain, physical function impairment, anxiety, depression, and low energy/fatigue – known collectively as the SPPADE symptoms – are common, co-occurring, and undertreated in cancer patients.
A large population study by Regenstrief Institute, Mayo Clinic and Yale University researchers examines the prevalence, severity, and co-occurrence of SPPADE symptoms as well as their association with cancer type and patient characteristics.
A total of 31,886 cancer patients were interviewed and assessed for SPPADE symptoms prior to, during or soon after an outpatient medical oncology appointment.
Symptoms were pervasive across all types of cancer and sociodemographics.
Among the study findings about the six SPPADE symptoms:
“It’s understandable that during a busy appointment, discussions of symptoms tend to focus on those that the physician considers more directly attributable to their disease and its treatment – such as nausea, vomiting, mouth sores, neuropathy – rather than SPPADE symptoms,” said Regenstrief Institute and Indiana University School of Medicine Research Scientist Kurt Kroenke, M.D., corresponding author of the new study.
“But it's important for cancer patients to know sleep disturbance, pain, physical function impairment, anxiety, depression and low energy/fatigue, while, perhaps, related to other factors in addition to their cancer, are not uncommon and that we have simple ways of measuring and effective ways of managing these often-debilitating symptoms.”
Dr. Kroenke is a pioneer and international leader in the field of symptomology.
He has co-developed brief survey measures in worldwide use to track symptoms of depression (PHQ-9); anxiety (GAD-7); suicide risk (P-4); and conditions common in older adults (SymTrak).
Some of these tools, which assist clinicians in selecting treatments and evaluating their effectiveness, have been translated into more than 100 languages.
He recently co-developed a brief item scale (the FSI-3) to measure cancer fatigue.
The study authors note, “Because SPPADE symptoms are highly prevalent and their effects relate more to morbidity and quality of life than mortality, it is important to minimise overdiagnosis while at the same time optimising treatment in patients most needing or desiring treatment. Thus, prioritising symptoms that warrant treatment should integrate several factors including symptom characteristics (severity, time course, treatability, rapidity of response) as well as patient preferences.”
“Prevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients with Cancer” is published in Journal of Pain and Symptom Management.
Source: Regenstrief Institute
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.